The emerging class of GLP-1 receptor agonist and GIP combined medications, including tirzepatide, semaglutide, and the recently introduced retatrutide, offer promising advances in diabetes control. https://mots-c-peptide985842.blog-tecnologia.com/62078617/semaglutide-a-detailed-examination